Rejuran, the salmon-DNA polynucleotide injectable made by Seoul-based Pharma Research, officially reached Israeli clinics in September 2025. What stands out is not that another K-beauty product arrived — several have — but how uniformly every tier of the Israeli rollout leans on one word: Korean.
One importer, one positioning#
The sole Israeli distributor is Omegamedix, which runs a dedicated landing page at rejuran.omegamedix.co.il and an Instagram account, @rejuran.israel. The landing page’s header reads:
REJURAN — הפולינוקליאוטיד המקורי מקוריאה (“REJURAN — the original polynucleotide from Korea”)
Below it: “ask your doctor for only this one” and “the #1 treatment in Korea for over 10 years”. The page cites three regulatory stamps — Israeli Ministry of Health approval, European CE MDR (received in the past year), and Korea’s KFDA — in that order, with the Korean regulator given equal billing.
The SKUs imported to Israel are Rejuran Healer (full face), Rejuran S (scars, including acne scars) and Rejuran I (eye area).
The Korean framing is the pitch#
In Israeli press, clinic copy and social media, the Korean origin is not a detail — it is the headline.
- Ynet Laisha ran a launch piece on 21 September 2025 titled “The Korean secret conquering Hollywood — REJURAN now in Israel”. The story (sponsored by Omegamedix) opens with a description of salmon runs in Gangwon province and quotes Ming Park, Pharma Research’s head of aesthetics, before adding: “The treatment reflects the familiar Korean philosophy: patience and natural results.”
- Mokasini published “Rejuran arrives in Israel: the Korean treatment that conquered Hollywood lands in the country” the week before.
- Maariv, same day as Ynet Laisha: “Fish DNA instead of Botox? The Korean treatment promising miracles”.
- Mako, 11 December 2025, placed Rejuran inside a broader frame: “Treating skin as sacred: how South Korea became a beauty superpower”.
- The @rejuran.israel Instagram markets it in Hebrew as “the talked-about Korean substance that conquered Asia, Australia and the US,” and in English as “the revolutionary Korean treatment.”
Clinic copy matches. Dr. Shabo: “Rejuran is an innovative substance originating in South Korea.” Dr. Zeid in Tel Aviv: “Rejuran is an advanced Korean treatment.” Dr. Orly Fuzailov, quoted in Ynetnews (English): “I’m among the first doctors to use the product, which comes from Korea… Koreans believe in slow and steady. In Israel, women have less patience.”
How much, and where#
Pricing — per Dr. Fuzailov and the skinbymichaela.co.il price page — runs roughly:
- Single 3cc face syringe: ₪3,000
- 2cc scar or eye syringe: ₪2,000
- Full initial course (3–4 sessions, 3–4 weeks apart): ₪7,000–15,000
- Maintenance: every 6–12 months
Israeli practices currently advertising Rejuran include Dr. Moshe Rosen (Tel Aviv + Jerusalem), Dr. Orly Fuzailov, Dr. Monica Elman (medical director of Maccabi Aesthetics), Dr. Shabo, Dr. Zeid (Tel Aviv), Skin by Michaela, Aestella Klinika and Menscape Clinic. It is not an exhaustive list — the Omegamedix Instagram directs patients to DM for the authorised-clinic roster.
Why this is worth noting#
Korean skincare brands have been on Israeli shelves for years — COSRX, Anua, Beauty of Joseon are in Super-Pharm — but those are drugstore goods. Rejuran is different: a prescription-only clinical injectable, priced at low-four figures per syringe, explicitly sold on its Korean provenance to Israeli consumers who until recently had only Italian and French polynucleotide alternatives. The launch is a notable data point in how Korean aesthetic medicine is crossing from “trendy” into Israeli medical practice, with the Korean origin carried through as a feature, not translated away.
Sources: Omegamedix, Ynet Laisha, Ynetnews, Mokasini, Maariv, Mako, Dr. Moshe Rosen.
